MXCT

MaxCyte, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-25

Figures on this page computed 2026-11-08 12:40 UTC

Last close

1.39USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-25

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-25
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
- 10-K for 2025, filed 2026-03-25
- 10-K for 2025, filed 2026-03-25
- 10-K for 2025, filed 2026-03-25
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-25
- 10-Q for 2025, filed 2026-08-13
The filing itself
-135.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
- 10-K for 2025, filed 2026-03-25
- 10-K for 2025, filed 2026-03-25
The filing itself
-109.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
- 10-K for 2025, filed 2026-03-25
- 10-K for 2025, filed 2026-03-25
The filing itself
0.10Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
- 10-K for 2025, filed 2026-03-25
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.35 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.17x

2.09x

1.97x

1.46x

0.32x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-25

Sales1.17x
Its own average over 10 years, 28.2M.
Profit2.09x
Its own average over 10 years, -21.3M.
Free cash flow1.97x
Its own average over 10 years, -18.4M.
Debt1.46x
Its own average over 7 years, 12.3M.
Price0.32x
Its own average over 6 years, 4. Market data, 2026-11-04

Profit is furthest from its own average, at 2.09 times.

Sales is 1.17 times its own 10-year average; Profit is 2.09 times its own 10-year average; Free cash flow is 1.97 times its own 10-year average; Debt is 1.46 times its own 7-year average; Price is 0.32 times its own 6-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-25

Sales against its own 10-year average1.17
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
The filing itself
Profit against its own 10-year average2.09
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.97
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
The filing itself
Debt against its own 7-year average1.46
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-034557
Reported in
USD
The filing itself
Price against its own 6-year average0.32Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD